Par Pharma receives FDA approval
for Generic Dostinex
29 December, 2005
Drug developer Par Pharmaceutical
Cos have announced on Thursday that the Food and Drug Administration
has given it final approval for its abbreviated new drug application
for cabergoline, a generic drug used to treat a hormone disorder
that often leads to infertility
in women and impotence or erectile
dysfunction in men.
The market of generic drugs is making huge profits nowadays. Cabergoline
is the generic version of Pfizer's Dostinex, which is used to treat
hyperprolactinemic disorders. Dostinex is an immensely usable drug
and its domestic sales exceeds $80 million a year, according to
Par pharma which is going to begin shipping cabergoline tablets
immediately for attaining maximum profit.
